Policy | September 06, 2021
TB Alliance partners with Lupin for non-exclusive anti-TB drug
According to WHO, over 1.5 million people died of TB in 2020
According to WHO, over 1.5 million people died of TB in 2020
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The drug is also intended for the treatment of glioblastoma multiforme
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively
Subscribe To Our Newsletter & Stay Updated
